SanBio, a stem cell and regenerative medicine company specializing in neurological disorders, announced that it has been issued a key patent by the Australian Patent Office covering its proprietary modified stem cells, SB623, for the treatment of traumatic brain injury. Australian Patent No. 2013263417 was formally issued on September 8, 2016.
To learn more, read the press release from SanBio below.
SanBio Granted Key Patent in Treatment for Traumatic Brain Injury
MOUNTAIN VIEW, Calif.–(Business Wire)–SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been issued a key patent by the Australian Patent Office covering its proprietary modified stem cells, SB623, for the treatment of traumatic brain injury. Australian Patent No. 2013263417 was formally issued on September 8, 2016.SanBio filed a global patent application after SB623 demonstrated its ability to promote, among other things, regenerative processes in the central nervous system and to provide therapeutic options for debilitating neurological disorders, including traumatic brain injury. Australia was the first country to grant the patent.
SanBio will continue to seek patent coverage for this stem cell treatment in other regions.
The effects of traumatic brain injury can be devastating, often requiring long-term rehabilitation and care to overcome severe neurological deficits, including cognitive and motor-function impairment. There currently are no approved medicines for the treatment of persistent motor disability from traumatic brain injury.
Said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, “There are 5.3 million people living with chronic disabilities from traumatic brain injury in the United States and more than 700,000 in Australia. We hope that SanBio’s regenerative medicine, SB623, will be able to serve as a treatment option for these patients.”
SanBio has also previously received patents protecting innovative methods for treating stroke and retinal degeneration with SB623 cells.
About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from ischemic stroke. SanBio also began a Phase 2 clinical trial for treatment of motor impairment resulting from traumatic brain injury in late 2015. More information about SanBio, Inc. is available at http://san-bio.com.
For SanBio, Inc.
Meredith Gallagher, 612-455-1724